The Stat3 inhibitor F0648-0027 is a potential therapeutic against rheumatoid arthritis
Yosuke Kaneko(Keio University), Takeshi Miyamoto(Kumamoto Health Science University), Kana Miyamoto(Kumamoto University), Yasuo Niki(Keio University), Shin-ichiro Ozawa(Kitasato University), Kengo Harato(Keio University), Tami Kobayashi(Keio University), Morio Matsumoto(Keio University Hospital), Shu Kobayashi(Keio University), Shuichi Hirono(Kitasato University), Masaya Nakamura(Keio University), Yuiko Sato(Keio University), Tatsuaki Matsumoto(Keio University)
Cited by 8
Related Papers
DC-STAMP is essential for cell–cell fusion in osteoclasts and foreign body giant cells
|The Journal of Experimental Medicine|2005|899
Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis
|Cell Metabolism|2006|771
Commitment and Differentiation of Osteoclast Precursor Cells by the Sequential Expression of C-Fms and Receptor Activator of Nuclear Factor κb (Rank) Receptors
|The Journal of Experimental Medicine|1999|694
v-ATPase V0 subunit d2–deficient mice exhibit impaired osteoclast fusion and increased bone formation
|Nature Medicine|2006|542
Transient receptor potential (<scp>TRP</scp>) channels: a clinical perspective
|British Journal of Pharmacology|2013|362